Fennec Pharmaceuticals Inc.
FENCNASDAQHealthcare● Active
$9.10
+$0.20(+2.25%)
Market Cap$260078228
P/E Ratio—
52W High$10.45
52W Low$5.65
Fennec Pharmaceuticals Inc. (FENC) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
FENC · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
$0.01
Est. -$0.02 · +150.0%
Revenue
$0.02B
Est. $0.01B · +8.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
FENC reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$3.83
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$3.83
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | $0.01 | — | — | — | $0.02B | — |
| ▲ Q2 FY2026 | May 14, 2026 | -$0.02 | $0.01 | +150.0% | $0.02B | $0.01B | +8.6% |
| ▼ Q1 FY2026 | Mar 24, 2026 | $0.03 | -$0.11 | -466.7% | $0.01B | $0.01B | -6.5% |
| ▲ Q4 FY2025 | Nov 13, 2025 | -$0.08 | -$0.02 | +75.0% | $0.01B | $0.01B | -15.2% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -$0.06 | -$0.11 | -83.3% | $0.01B | $0.01B | +0.9% |
| ▲ Q2 FY2025 | May 13, 2025 | -$0.12 | -$0.04 | +66.7% | $0.01B | $0.01B | -3.2% |
| ▼ Q1 FY2025 | Mar 10, 2025 | $0.56 | -$0.06 | -110.7% | $0.01B | $0.01B | +1.6% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.13 | -$0.21 | -61.5% | $0.01B | $0.01B | -12.9% |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
$0.01
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Beat
EPS Actual
$0.01
EPS Est.
-$0.02
EPS Surpr.
+150.0%
Revenue
$0.02B
Q1 FY2026
Mar 24, 2026Miss
EPS Actual
-$0.11
EPS Est.
$0.03
EPS Surpr.
-466.7%
Revenue
$0.01B
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
-$0.02
EPS Est.
-$0.08
EPS Surpr.
+75.0%
Revenue
$0.01B
Q3 FY2025
Aug 14, 2025Miss
EPS Actual
-$0.11
EPS Est.
-$0.06
EPS Surpr.
-83.3%
Revenue
$0.01B
Q2 FY2025
May 13, 2025Beat
EPS Actual
-$0.04
EPS Est.
-$0.12
EPS Surpr.
+66.7%
Revenue
$0.01B
Q1 FY2025
Mar 10, 2025Miss
EPS Actual
-$0.06
EPS Est.
$0.56
EPS Surpr.
-110.7%
Revenue
$0.01B
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$0.21
EPS Est.
-$0.13
EPS Surpr.
-61.5%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.36 | $0.38 | $0.42 | 2 |
| Q3 FY2028 | $0.31 | $0.33 | $0.36 | 2 |
| Q2 FY2028 | $0.20 | $0.21 | $0.23 | 2 |
| Q1 FY2028 | $0.16 | $0.17 | $0.19 | 2 |
| Q4 FY2027 | $0.27 | $0.29 | $0.32 | 1 |
| Q3 FY2027 | $0.23 | $0.24 | $0.27 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 14, 2026 | +150.0% | $6.77 | $9.24 | +36.48% |
| ▼ Q1 FY2026 | Mar 24, 2026 | -466.7% | $7.45 | $6.02 | -19.19% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +75.0% | $7.78 | $7.69 | -1.16% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -83.3% | $9.11 | $8.53 | -6.37% |
| ▲ Q2 FY2025 | May 13, 2025 | +66.7% | $6.27 | $6.48 | +3.35% |
| ▼ Q1 FY2025 | Mar 10, 2025 | -110.7% | $6.88 | $6.11 | -11.19% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -61.5% | $4.95 | $4.36 | -11.92% |
| ▼ Q3 FY2024 | Aug 13, 2024 | -433.3% | $6.25 | $5.85 | -6.40% |
Q2 FY2026+36.48%
Report Date
May 14, 2026
EPS Beat/Miss
+150.0%
Price Before
$6.77
Price After
$9.24
Q1 FY2026-19.19%
Report Date
Mar 24, 2026
EPS Beat/Miss
-466.7%
Price Before
$7.45
Price After
$6.02
Q4 FY2025-1.16%
Report Date
Nov 13, 2025
EPS Beat/Miss
+75.0%
Price Before
$7.78
Price After
$7.69
Q3 FY2025-6.37%
Report Date
Aug 14, 2025
EPS Beat/Miss
-83.3%
Price Before
$9.11
Price After
$8.53
Q2 FY2025+3.35%
Report Date
May 13, 2025
EPS Beat/Miss
+66.7%
Price Before
$6.27
Price After
$6.48
Q1 FY2025-11.19%
Report Date
Mar 10, 2025
EPS Beat/Miss
-110.7%
Price Before
$6.88
Price After
$6.11
Q4 FY2024-11.92%
Report Date
Nov 7, 2024
EPS Beat/Miss
-61.5%
Price Before
$4.95
Price After
$4.36
Q3 FY2024-6.40%
Report Date
Aug 13, 2024
EPS Beat/Miss
-433.3%
Price Before
$6.25
Price After
$5.85
Avg Beat Reaction+12.89%
Avg Miss Reaction-11.01%
Beat Rate3 / 8 quarters
Largest Move+36.48% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: FENC ends December
Fennec Pharmaceuticals Inc. (FENC) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $0.01 — beating the analyst consensus of $-0.02 by +150.0%. The next FENC earnings date is expected around September 1, 2026.
Each quarter, investors track FENC earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. FENC revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
FENC's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
FENC earnings · 5 questionsFennec Pharmaceuticals Inc.'s next earnings report is expected around September 1, 2026. FENC typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; FENC historically reports after market close (AMC).
FENC earnings datewhen is FENC earningsFENC next earnings datewhen does FENC report earningsFENC earnings calendar
▸ Source: FMP · Fennec Pharmaceuticals Inc. SEC filings · US GAAP · Fennec Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026